CN115135649A - 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 - Google Patents
包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 Download PDFInfo
- Publication number
- CN115135649A CN115135649A CN202180015038.4A CN202180015038A CN115135649A CN 115135649 A CN115135649 A CN 115135649A CN 202180015038 A CN202180015038 A CN 202180015038A CN 115135649 A CN115135649 A CN 115135649A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- pharmaceutically acceptable
- acceptable salt
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
一种包括吡啶并[1,2‑a]嘧啶酮化合物的药物组合。具体而言，该药物组合包括式(I)化合物或其药学上可接受的盐和氟维司群或其药学上可接受的盐。涉及该药物组合、或式(I)化合物或其药学上可接受的盐单独使用在治疗乳腺癌患者中的用途。
Description
PCT国内申请，说明书已公开。
Claims (28)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010161911 | 2020-03-10 | ||
| CN2020101619118 | 2020-03-10 | ||
| PCT/CN2021/079908 WO2021180111A1 (zh) | 2020-03-10 | 2021-03-10 | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115135649A true CN115135649A (zh) | 2022-09-30 |
Family
ID=77670987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180015038.4A Pending CN115135649A (zh) | 2020-03-10 | 2021-03-10 | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230119759A1 (zh) |
| EP (1) | EP4119557A4 (zh) |
| CN (1) | CN115135649A (zh) |
| WO (1) | WO2021180111A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116761608A (zh) * | 2020-12-08 | 2023-09-15 | 正大天晴药业集团股份有限公司 | 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途 |
| WO2023051725A1 (zh) * | 2021-09-30 | 2023-04-06 | 广州嘉越医药科技有限公司 | 一种药物组合及其应用 |
| US20240108579A1 (en) * | 2021-12-31 | 2024-04-04 | Chengdu Biostar Pharmaceuticals, Ltd. | Utidelone liposome composition, and preparation method therefor and use thereof |
| WO2023169488A1 (zh) * | 2022-03-09 | 2023-09-14 | 正大天晴药业集团股份有限公司 | 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| CN103070871B (zh) * | 2011-10-26 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 一种氟维司群的药物组合物 |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| AU2015276699B2 (en) | 2014-06-17 | 2019-10-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor |
| KR20180095565A (ko) * | 2015-12-16 | 2018-08-27 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 피리도[1,2-a]피리미돈 유사체, 이의 결정형, 이의 중간체 및 이의 제조방법 |
-
2021
- 2021-03-10 CN CN202180015038.4A patent/CN115135649A/zh active Pending
- 2021-03-10 EP EP21767461.3A patent/EP4119557A4/en active Pending
- 2021-03-10 WO PCT/CN2021/079908 patent/WO2021180111A1/zh unknown
- 2021-03-10 US US17/906,017 patent/US20230119759A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230119759A1 (en) | 2023-04-20 |
| EP4119557A4 (en) | 2024-04-10 |
| WO2021180111A1 (zh) | 2021-09-16 |
| EP4119557A1 (en) | 2023-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115135649A (zh) | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 | |
| TWI607754B (zh) | 醫藥組合 | |
| WO2018229130A1 (en) | Compounds for treating tnbc | |
| US20230330106A1 (en) | Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant | |
| WO2019057141A1 (zh) | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2022057812A1 (zh) | 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途 | |
| EP4098251A1 (en) | Use of mitoxantrone hydrochloride liposome for treating breast cancer | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| CN110585429B (zh) | 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途 | |
| CN115190800A (zh) | 一种brd4抑制剂的用途 | |
| CN115038447A (zh) | 用于治疗癌症的组合疗法 | |
| RU2777519C2 (ru) | Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы | |
| CN114761010B (zh) | 喹唑啉衍生物或其盐的联用药物组合物及其用途 | |
| EP3766496A1 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| WO2023051606A1 (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| WO2022121929A1 (zh) | 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途 | |
| WO2021185234A1 (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
| CN115003674A (zh) | 吡啶并[1,2-a]嘧啶酮化合物的治疗淋巴瘤的用途 | |
| CN113797342A (zh) | 用于预防或治疗肿瘤疾病的治疗剂组合 | |
| US20030139430A1 (en) | Use of organic compounds | |
| CN118019537A (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| CN117357528A (zh) | 一种激酶抑制剂的新用途 | |
| WO2021083347A1 (zh) | 喹唑啉衍生物或其盐、或其药物组合物的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |